Yao L, Tang S J
Clinic and Research Centre of Tuberculosis, Shangnai Clinical Research Centre for Infectious Disease, Tongji University School of Medicine, Shanghai 200433, China.
Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Research Institute, Beijing 101149, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Feb 12;48(2):170-175. doi: 10.3760/cma.j.cn112147-20241016-00615.
China remains one of the countries with a high burden of tuberculosis (TB), with an estimated 748, 000 cases each year, ranking third in the world. The research and development of new drugs and new protocols plays a key role in the face of the requirements of the WHO's End TB Strategy. There are multiple new drugs in the clinical trial stage, such as macozinone, sutezoid, alpiberctin, and GSK3036656. The effectiveness, safety, and resistance issues of marketed drugs such as linezolid, bedaquiline, and delamanid are also of great concern. Meanwhile, short-term treatments for sensitive and drug-resistant TB have always been a hot topic in clinical research. WHO has also updated the preventive treatment plan for people at high risk of TB. This article reviews the literature published from October 1, 2023 to September 30, 2024.
中国仍是结核病高负担国家之一，每年估计有74.8万例病例，位居世界第三。面对世界卫生组织终结结核病战略的要求，新药和新方案的研发起着关键作用。有多种新药处于临床试验阶段，如马佐西酮、舒泰唑胺、阿利贝星和GSK3036656。利奈唑胺、贝达喹啉和德拉马尼等已上市药物的有效性、安全性和耐药性问题也备受关注。与此同时，敏感和耐药结核病的短期治疗一直是临床研究的热点话题。世界卫生组织还更新了结核病高危人群的预防性治疗方案。本文综述了2023年10月1日至2024年9月30日发表的文献。
